Innovator國際已開發動力緩衝主動型ETF-3月 IMAR 深 滬
等待開盤 03-26 09:30:00 美东时间
28.9713
+0.240
+0.83%
華盛通- 最 高29.10
- 今 開28.97
- 成交量 9688股
- 最 低 28.8701
- 昨 收 28.7318
- 總市值 6373.69万
- 52周最高 30.54
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 24.6018
- 委 比 -33.33%
- 總股本 220.00万
- 歷史最高 30.54
- 量 比 0.25
- 振 幅 0.80%
- 歷史最低 24.6018
- 每 手 1
- 風險率 1.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer
BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer March 25 (Reuters) - US FDA: FDA APPROVES RELACORILANT WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER F
03-25 22:59
BRIEF-Bayer Says Finerenone Meets Primary Endpoint In Investigational Phase III FIND-CKD Study
BRIEF-Bayer Says Finerenone Meets Primary Endpoint In Investigational Phase III FIND-CKD Study March 16 (Reuters) - BAYER AG BAYGn.DE : KERENDIA® (FINERENONE) MEETS PRIMARY ENDPOINT IN INVESTIGATIONAL PHASE III FIND-CKD STUDY IN PATIENTS WITH NON-DIABETIC CHRONIC KIDNEY DISEASE DEMONSTRATING A STATI
03-16 15:32
BRIEF-Meta To Deploy 4 New Generations Of MTIA Chips Within Next 2 Years
BRIEF-Meta To Deploy 4 New Generations Of MTIA Chips Within Next 2 Years March 11 (Reuters) - Meta Platforms Inc META.O : EXPANDING META’S CUSTOM SILICON TO POWER OUR AI WORKLOADS META- DEPLOYING 4 NEW GENERATIONS OF MTIA CHIPS WITHIN NEXT 2 YRS TO SUPPORT RANKING & RECOMMENDATIONS, ALONG WITH GENAI
03-11 22:05
BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity
BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity March 10 (Reuters) - Ascletis Pharma Inc 1672.HK : ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE II, 24-WEEK STUDY FOR ITS ULTRA-LONG-ACTING SUBCUTANEOUS DEPO
03-10 18:06
BRIEF-United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction In Risk Of Clinical Worsening In Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
BRIEF-United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction In Risk Of Clinical Worsening In Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy March 2 (Reuters) - United Therapeutics Corp UTHR.O : UNITED THERAPEUTICS
03-02 22:10
BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Affirm Study Evaluating Skyrizi® (Risankizumab) Subcutaneous Induction In Patients With Crohn's Disease
BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Affirm Study Evaluating Skyrizi® (Risankizumab) Subcutaneous Induction In Patients With Crohn's Disease March 2 (Reuters) - Abbvie Inc ABBV.N : ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 AFFIRM STUDY EVALUATING SKYRIZI® (RISANK
03-02 21:32
BRIEF-U.S. Aluminum Co Signs Agreement With EGA And Century Aluminum
BRIEF-U.S. Aluminum Co Signs Agreement With EGA And Century Aluminum Feb 24 (Reuters) - EGA: EGA - OKLAHOMA’S BURGEONING ALUMINUM HUB GETS BOOST WITH AGREEMENT BETWEEN U.S. ALUMINUM CO AND EGA, CENTURY ALUMINUM EGA- CONSTRUCTION OF OKLAHOMA PRIMARY ALUMINUM EXPECTED TO BEGIN BY END OF 2026 EGA- EGA,
02-24 23:14
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept Feb 23 (Reuters) - Bristol-Myers Squibb Co BMY.N : BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOP-LINE RESULTS FROM REGISTRATIONAL PHASE 2 STUDY OF LUSPATERCEPT IN ADULTS WITH ALPHA (Α)-THAL
02-23 20:18
BRIEF-Aimia Announces Dual Listing On Johannesburg Stock Exchange
BRIEF-Aimia Announces Dual Listing On Johannesburg Stock Exchange Feb 17 (Reuters) - Aimia Inc AIM.TO : AIMIA ANNOUNCES DUAL LISTING ON JOHANNESBURG STOCK EXCHANGE AIMIA INC - TO TRADE ON JSE UNDER SHARE CODE 'AII' AIMIA INC - MAINTAINS PRIMARY LISTING ON TSX, NO CAPITAL RAISE WITH ITS SECONDARY LIS
02-17 19:33
BRIEF-Celon Pharma Says FDA Deems Phase III Study Concept For CPL'36 Treatment Reasonable
BRIEF-Celon Pharma Says FDA Deems Phase III Study Concept For CPL'36 Treatment Reasonable Feb 13 (Reuters) - Celon Pharma SA CLNP.WA : ANNOUNCES COMPLETION OF ANALYSIS OF WRITTEN RESPONSES FROM FDA REGARDING CPL'36 FOR PARKINSON'S DISEASE-INDUCED DYSKINESIA (PD-LID) FDA DEEMS PROPOSED PHASE III STUD
02-14 00:18
